Latest Remuneration News

AMCIL and AFIC announce a major leadership transition as long-serving CEO Mark Freeman retires, with Alison Gibson appointed to succeed him in July 2026.

Mark Freeman, the long-serving CEO of Mirrabooka Investments and AFIC, is set to retire at the end of 2026, with Alison Gibson appointed as his successor. Gibson’s return marks a significant leadership transition for these major listed investment companies.

Djerriwarrh Investments and Australian Foundation Investment Company announce a major leadership change as Mark Freeman retires and Alison Gibson steps in as CEO and Managing Director.

Australian Foundation Investment Company (AFIC) announces the retirement of long-serving CEO Mark Freeman and the appointment of Alison Gibson as his successor, marking a significant leadership transition for the $12 billion investment firm.

GreenTech Metals has appointed James Rattenbury as CEO to spearhead development of its Munni Munni platinum group metals project, signalling a strategic push in the West Pilbara mining hub.

Emu NL has reversed its previous decision to terminate Doug Grewar, reinstating him as CEO and Managing Director with a new contract focused on advancing the Yataga Copper Project.

SportsHero Limited has raised $4.3 million through a private placement, including a significant commitment from its CEO, to accelerate its HeroPlay rollout across Southeast Asia.

Australian Clinical Labs reported a modest revenue dip but achieved growth in earnings and margins in 1H26, while updating FY26 guidance and addressing wage increases mandated by the Fair Work Commission.

Galilee Energy has launched an offer of up to 464 million new options to participants in its recent $6.5 million placement, aiming to bolster exploration funding and working capital. The options, exercisable at $0.011 each over three years, come amid significant operational and market risks.

PeopleIN Limited has appointed co-founder Tom Reardon as its new CEO and Managing Director, signaling continuity in leadership as the company reports a robust unaudited EBITDA of $16.1 million.

Podium Minerals has disclosed the initial securities interests of its newly appointed directors, highlighting a significant allocation of performance rights to Gary Humphries while Neal Froneman holds none.

OncoSil Medical’s CEO Nigel Lange has agreed to a 10% salary reduction, opting instead to receive shares at a significant premium, reinforcing executive commitment to shareholder value and cost discipline.